GlassScriptPhysician profile
Neal C Gehani
NPI 1841484862
$4,311.03
in general payments reported to CMS, 2019-2025
29 companies · $1,030 in 2025
The $1,030 reported for 2025 was more than what 80% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $197 · 2021: $245 · 2022: $516 · 2023: $828 · 2024: $1,271 · 2025: $1,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,030 · Education: $98.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,030.28 |
| Education | $98.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurent Medical Limited | $703.91 | 2023-2025 | Neuromark Radiofrequency Console, Neuromark Device, Neuromark System |
| Glaxosmithkline, LLC. | $703.83 | 2019-2025 | Nucala |
| Aerin Medical INC. | $542.90 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $366.81 | 2023-2025 | Dupixent |
| Optinose US, INC. | $297.87 | 2022-2025 | |
| Genzyme Corporation | $287.31 | 2021-2025 | |
| Kaleo, INC. | $208.00 | 2019-2024 | Auvi-Q |
| Hikma Pharmaceuticals USA | $149.31 | 2023-2025 | Ryaltris |
| Medtronic, INC. | $140.54 | 2024-2025 | Stealthstation S8 Platform, Propel, Nuvent |
| Amgen INC. | $119.75 | 2024 | Tezspire |
| Astrazeneca Pharmaceuticals LP | $81.75 | 2022-2023 | Tezspire |
| Alk-Abello, INC | $77.23 | 2019-2025 | Grastek, Odactra, Ragwitek |
| Integra Lifesciences Corporation | $74.43 | 2024-2025 | Trudi Probe, Relieva Spinplus Nav, Inspira Air |
| Novartis Pharmaceuticals Corporation | $69.44 | 2019-2023 | |
| Intersect Ent, INC. | $60.00 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acclarent, INC | $44.89 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $44.80 | 2025 | Neffy |
| Incyte Corporation | $43.41 | 2021-2024 | Opzelura |
| Teva Pharmaceuticals USA, INC. | $43.07 | 2020 | |
| Stryker Corporation | $41.35 | 2019 | |
| Medtronic USA, INC. | $39.53 | 2019-2020 | |
| Phadia US INC. | $33.61 | 2023-2024 | Immunocap |
| Abbvie INC. | $30.99 | 2024 | |
| Pfizer INC. | $22.81 | 2023 | |
| Biocryst US Sales Co., LLC | $21.43 | 2025 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $20.32 | 2020 | |
| Genentech USA, INC. | $15.09 | 2025 | Xolair |
| Glenmark Therapeutics INC. | $14.00 | 2019 | |
| Eyevance Pharmaceuticals LLC | $12.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neal Gehani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.